AIM ImmunoTech Inc 2024年度报告

FORM10-K ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 For the fiscal year endedDecember 31,2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No.001-27072 AIM IMMUNOTECH INC. (Exact name of registrant as specified in its charter) Securities registered pursuant to Section 12(g) of the Act:(Title of Each Class)NONE Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☒No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company oran emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act: ☐Accelerated filer☒Smaller reporting company☐Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☐ Indicate by checkmark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included inthe filing reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensationreceived by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2024, the last business day of theregistrant’s most recently completed second fiscal quarter was $20,793,354. The number of shares of the registrant’s Common Stock outstanding as of March 24, 2025 was72,290,030. DOCUMENTS INCORPORATED BY REFERENCE:None. TABLE OF CONTENTS PagePART IITEM 1. Business.3ITEM 1A. Risk Factors.22ITEM 1B. Unresolved Staff Comments.36ITEM 1C. Cybersecurity36ITEM 2. Properties.36ITEM 3. Legal Proceedings.37ITEM 4. Mine Safety Disclosures.37PART IIITEM 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.38ITEM 6. [Reserved]38ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.38ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk.43ITEM 8. Financial Statements and Supplementary Data.43ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.43ITEM 9A. Controls and Procedures.43ITEM 9B. Other Information.44ITEM 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.44PART IIIITEM 10. Directors, Executive Officers and Corporate Governance.45ITEM 11. Executive Compensation.52ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.61ITEM 13. Certain Relationships and Related Transactions and Director Independence.63ITEM 14. Principal Accountant Fees and Services.63PART IVITEM 15. Exhibits and Financial Statement Schedules.64ITEM 16. Form 10-K Summary.702 ITEM 1.Business GENERAL AIMImmunoTech Inc.and its subsidiaries(collectively,“AIM”,“Company”,“we”or“us”)are an immuno-pharma companyheadquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases andimmune-deficiency disorders and to treat cancers for which there are